Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
A new wave of 'age-reversing' pills is upon us. Should we bite?
NMN, a substance under development as a drug, has shown promise in reducing inflammation and improving physical performance in small-scale human trials, but its efficacy remains uncertain. Longevity expert Dr. Lindsay Wu warns against premature use, especially in IVF treatments. A recent review found NMN safe but cautioned against market hype, particularly for skin rejuvenation claims. The US Interventions Testing Program highlights the discrepancy between rodent and human longevity studies, with rapamycin being the only drug consistently shown to increase mammalian lifespan, though it may compromise muscle mass.
Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro
Asia Deal Watch: Kaken acquires Aadi subsidiary and cancer drug Fyarro. Other deals include Hangzhou DAC/Aadi, Astellas/Sangamo, Kyorin/Bayer, Eisai/Newron, Lupin/Boehringer Ingelheim, Asahi Kasei/Chiome.
7 breakthrough findings reveal new ways to delay menopause naturally
New research offers hope for delaying menopause, potentially extending fertility and improving health outcomes. Discoveries include ovarian preservation, rapamycin's effects, hormonal balance benefits, and quality of life improvements. These advancements could transform women's reproductive health and aging process.
Macaque Lives over Six Months with Pig Kidney in Chinese Study
Chinese scientists achieved 184 days of organ function in a macaque with a gene-edited pig kidney transplant, using an improved immunosuppressive regimen. This milestone positions China competitively in xenotransplantation research, aiming for human trials.
Biotechnology and science require long-term investment, and we are still in ...
Binance Labs hosted DeSci Day in Bangkok, gathering 50 biotech and DeSci enthusiasts. Speakers discussed biotech development, rapamycin, longevity, citizen science, bioDAO, on-chain IP, and AI agents. VitaDAO launched a longevity supplement, and HairDAO is scaling up. CZ and Vitalik participated in an open Q&A. Binance Labs emphasizes long-term investment in biotech and crypto integration.
Is rapamycin the next big breakthrough in periodontitis and oral cancer treatment?
Dr. Jonathan An's FDA-approved study on rapamycin in periodontitis patients measures microbiome and biological clock changes, building on rapamycin's antiaging effects seen in mice. Rapamycin's inhibition of mTOR reduces oxidative stress, potentially aiding tissue regeneration and oral cancer treatment by suppressing tumor growth and enhancing other therapies.
Breakthrough in Brain Aging: Scientists Reverse Aging in Fruit Flies by Blocking Common ...
A study in Nature Communications shows that F-actin buildup in fruit fly brains inhibits cellular recycling, leading to cognitive decline. By reducing F-actin through genetic tweaks, researchers extended fruit flies' healthy lifespan by 30%, suggesting F-actin impairs autophagy and drives brain aging.
A doctor weighs in on anti-agers using rapamycin to extend their lives
Rapamycin, typically used for organ transplant patients, has shown potential for longevity in mice, fruit flies, and worms. Dr. Andrea Maier cautions its off-label use for aging, citing lack of knowledge and potential side effects. Clinical trials are ongoing to explore its impact on age-related diseases like Alzheimer's, but Maier advises against its widespread use without FDA approval.
Related Clinical Trials:
Exploring the Benefits of Nab-Sirolimus in Advanced PEComa Treatment
Nab-sirolimus, an mTOR inhibitor, was FDA-approved in 2021 for advanced malignant PEComa, showing a 39% response rate in the AMPECT trial. It does not require biomarker testing, offering broader access, though TSC-2 mutations correlate with better responses. Adverse events are generally mild, with low discontinuation rates. Monitoring involves imaging every 3 months, and managing mucositis includes good oral hygiene and supportive care.
Related Clinical Trials:
National Academy of Medicine Elects 100 New Members
NAM elected 90 regular and 10 international members, recognizing outstanding achievements in health and medicine. New members include Carlos L. Arteaga, Nina Bhardwaj, Bob S. Carter, Stephen Jacob Chanock, George Coukos, Lisa M. Coussens, Silvia C. Formenti, Joseph Heitman, Nola M. Hylton, Reshma Jagsi, Peter Anthony Jones, Funda Meric-Bernstam, Deborah Schrag, and Mitchell J. Weiss. Victor J. Dzau, NAM President, highlighted their contributions to health equity and public health challenges.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath